Education
About Us
Working with TipRanks
Follow Us
SciBase Holding AB (DE:5J3)
FRANKFURT:5J3
5J3 Stock Chart & Stats
€0.04
<€0.01(5.00%)
At close: 4:00 PM EST
€0.04
<€0.01(5.00%)
Day’s Range― - ―
52-Week Range€0.00 - €0.04
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€20.86M
Enterprise Value€84.00M
Total Cash (Recent Filing)€24.76M
Total Debt (Recent Filing)€652.00K
Price to Earnings (P/E)―
Beta5.62
Next Earnings
Feb 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding828,365,200
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.99
Price to Sales (P/S)2.46
P/FCF Ratio-1.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained top-line expansion (~36% TTM) signals successful commercial traction for Nevisense. Durable revenue growth helps scale the installed base, increases recurring consumable pull-through, and provides a structural runway to leverage fixed-costs and improve long-term profitability if sustained.
Product-Level MarginsHigh gross margins (~66% TTM) indicate strong unit economics for the Nevisense platform and consumables. This margin cushion is durable, allowing the company to invest in sales/clinical adoption while preserving gross profit as volumes rise, aiding a sustainable path toward operating leverage.
Low Financial LeverageVery low debt (debt-to-equity ~0.01) lowers solvency and interest-rate risk, preserving strategic optionality. Structurally, low leverage reduces fixed financial obligations and gives management flexibility to raise capital on favorable terms or prioritize investment in commercialization without heavy near-term interest burdens.
Bears Say
Deep Operating And Net LossesExtremely negative operating and net margins show the cost base far exceeds revenue today. These structural losses erode equity and imply the company must materially improve margins or scale revenue quickly to reach sustainable profitability; otherwise losses will persist as a long-term drag.
Severe Cash BurnTrailing-twelve-month operating and free cash flow around -76M indicates persistent negative cash generation. This structural cash burn makes the business dependent on external financing, increases dilution risk, and constrains the firm's ability to fund commercialization and R&D from internal cash flow.
Negative Returns And Equity ErosionA deeply negative ROE (~-249%) signals ongoing shareholder value destruction and indicates current operations fail to generate returns on invested capital. Over months this raises the probability of dilutive capital raises and limits capacity to self-fund growth, pressuring long-term financial stability.
SciBase Holding AB News
5J3 FAQ
What was SciBase Holding AB’s price range in the past 12 months?
SciBase Holding AB lowest stock price was €0.00 and its highest was €0.04 in the past 12 months.
What is SciBase Holding AB’s market cap?
SciBase Holding AB’s market cap is €20.86M.
When is SciBase Holding AB’s upcoming earnings report date?
SciBase Holding AB’s upcoming earnings report date is Feb 24, 2026 which is today.
How were SciBase Holding AB’s earnings last quarter?
Currently, no data Available
Is SciBase Holding AB overvalued?
According to Wall Street analysts SciBase Holding AB’s price is currently Overvalued.
Does SciBase Holding AB pay dividends?
SciBase Holding AB does not currently pay dividends.
What is SciBase Holding AB’s EPS estimate?
SciBase Holding AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SciBase Holding AB have?
SciBase Holding AB has 828,365,200 shares outstanding.
What happened to SciBase Holding AB’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of SciBase Holding AB?
Currently, no hedge funds are holding shares in DE:5J3
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SciBase Holding AB
SciBase Holding AB (publ), a medical technology company, develops and sells instruments for the detection of skin cancer and other skin conditions in Europe and internationally. Its product includes Nevisense and Nevisense Go, a point of care platform that addresses in the areas of melanoma detection, non-melanoma skin cancer detection, and skin barrier assessment. The company has a collaboration agreement with Advanced Dermatology and Cosmetic Surgery (ADCS) group. SciBase Holding AB (publ) was founded in 1998 and is headquartered in Sundbyberg, Sweden.
Technical Analysis
Clinical Laserthermia Systems AB Class B
―
Luxbright AB
―
Arcoma AB
―
Neola Medical AB
―
Iconovo AB
―